Heartseed (219A) · InitiativeCited as achieved
Licensing expansion for undifferentiated iPS cell removal technology
First written in FY2024. 1 of 2 entries say "Cited as achieved", first in FY2025. Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Licensing expansion for undifferentiated iPS cell removal technologyA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025Cited as achievedAnnual report
「In September 2023, we announced that we had out-licensed a purification technology using a fatty acid synthesis inhibition method to a company developing therapeutic products by producing cells other than cardiomyocytes from iPS cells.」
The Company has cited its September 2023 out-licensing of the fatty acid synthesis inhibition method to a company targeting cells other than cardiomyocytes as an example of platform technology utilization. - FY2024First statedAnnual report
「We intend to license our metabolic selection patents to companies that use, or wish to use, them in fields other than myocardial regeneration therapy, thereby contributing to the practical application of cell therapies using iPS cells.」
The Company is pursuing licensing, monetization and expansion into other fields for its metabolic selection technology, which removes residual undifferentiated iPS cells.